Unwana and Sunday O Awofisayo
Department of Clinical Pharmacy and Biopharmacy, Faculty of pharmacy, University of Uyo
Correspondence: Unwana

Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of uyo


Erectile dysfunction (ED) also called impotence is characterized by the inability of the man to develop or maintain an erection of sufficient rigidity for satisfactory sexual intercourse. Erection occurs when blood flows into the penis thereby increases it making the penis larger and firmer. The combinations of hormones, blood vessels, nerves and muscles all work together to cause an erection. When the brain senses a sexual urge, it starts an erection by sending nerve signals to the penis. The nerve signal causes the muscles in the penis to relax and allows blood flow into the sponge tissues in the penis. Blood collects in this tissue like water filling a sponge. The penis becomes larger and firmer like a blown up balloon. The vein shut off to keep blood from flowing out. An erection requires healthy blood vessels. After orgasm or when the man is no longer aroused, the veins open up and blood flows back into the body. This review examines the failure of the penis to function this way leading to erectile dysfunction.


Erectile dysfunction has been profoundly defined as the inability to achieve or maintain an erection sufficiently rigid for satisfying sexual intercourse ( ). Erectile dysfunction can have a profound negative impact on the quality of life and life satisfaction of the patient resulting in fear, loss of self image and self confidence and depression. Erectile dysfunction can occur if one gets an erection sometimes and not every time or an erection that does not last enough for sex or unable to get an erection at all.


An estimated 150 million men worldwide have some degree of ED and more than twice that many are expected to be affected by 2025 ( ). The exact number of persons with ED may be underestimated by reason of the stigma that goes with the disease. In Africa , surveys of men between the ages of 35 and 70 years requesting primary medical care indicated that the prevalences of ED were 57.4% in Nigeria and 63.6% in Egypt ( ).


Neurological problems resulting from trauma to the parasympathetic nerves from prostate surgical procedures have suffered ED. A number of cases of persons from post surgery experiences of ED have been documented. In the same vein, drugs such as nozotine, alcohol and antidepressants have been reported as causes of Ed ( ).
In men older than age 40, ED is most often caused by an underlying vascular disease. As discussed previously adequate blood flow is essential for penile erection. Vascular disease which can occur as a result of uncontrolled hypertension, Diabetes Mellitus and artherosclerosis reduce the ability of the body’s blood vessels including those in the penis to dilate ( ). Part of this impaired vasodilation is due to decreased release of nitric oxide ( ).
Psychological conditions such as stress, anxiety and depression can contribute to ED ( ). Prolonged bicycling which compress the nerves and affect blood to the penis can lead to temporary ED.


Erectile dysfunction can lead to various complications such as impotence, embarrassment, low self esteem, loss of confidence and fear.

In the treatment of erectile dysfunction, there are non pharmacological and pharmacological treatments. Non pharmacological treatment involves advising the patient on the underlying cause of the dysfunction, and low to do away with these underlying causes. The following measures including abstinence from alcohol, eating of food that will increase nitric oxide formation. Nitric oxide has been documented to be of immense importance to the functionality of the physiology of the Penis. Treatment of the hypertension and diabetes if present is of utmost importance in the management of ED. Exercise improves the flow of blood to the penis and this has been reported to be of advantage. Healthy eating habits and meals containing fruits and vegetables are advantageous. Smoking and the use of illegal drug are deleterious and are associated with ED.


This involves the use of drug which are divided into 3 classes namely the phosphoodiesterase inhibitors including sidenafil (viagra, vega, embagra), vardenafil and tadalafil (tadalis, honinhil).


Tadalafil is used as a treatment for adult men with ED. It contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitor. Following sexual stimulation it works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis.. Common side effects are headache, indigestion, facial flushing, muscle pain, back pain, nasal congestion. Combination of these drugs may lead to comma and sometimes death.


1. Mcvary KT; Clinical practice. Erectile dysfunction, N Engl Med 357: 2472, 2007
2. Malzuk M, Lamb D; The biology of infertility: research advances and clinical challenges, Nat Med 14: 1197, 2008.
3. Virag R, Zwang G, Dermange H, Legman M. Vasculogenic impotence: a review of 92 cases with 54 surgical operations. Vasc Surg. 1981;15:9–17.
4. Glina S, Shindel A, Eardley I, Ghanem H. Cavernosal α-blockade: a new technique for investigating and treating erectile impotence by GS Brindley. J Sex Med. 2008;5:1791–1794.
5. Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973;2:80–82.
6. Blumenthal SA. Earl Sutherland (1915–1974) [corrected] and the discovery of cyclic AMP. Perspect Biol Med. 2012;55:236–249.
7. Ballard SA, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164–2171.
8. Gandaglia G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65:968–978.
9. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61. This seminal manuscript defines the prevalence of erectile dysfunction.
10. Corona G, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS) J Sex Med. 2010;7:1362–1380.
11. Rosen R, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol. 2003;44:637–649. This publication describes the relationship of LUTS and erectile dysfunction.
12. Nicolosi A, et al. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology. 2004;64:991–997.
13. Laumann EO, et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17:39–57. An international study evaluating different aspect of sexual difficulties and some associated predictors.
14. Shabsigh R, Perelman MA, Lockhart DC, Lue TF, Broderick GA. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol. 2005;174:662–667.
15. Johannes CB, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460–463.
16. Moreira ED, et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61:431–436.
17. Schouten BW, et al. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen study. Int J Impot Res. 2005;17:58–62.
18. Seftel AD, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67:32–45.
19. Gacci M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60:809–825.
20. Corona G, Rastrelli G, Maseroli E, Forti G, Maggi M. Sexual function of the ageing male. Best Pract Res Clin Endocrinol Metab. 2013;27:581–601
21. Jannini EA, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries. J Sex Med. 2014;11:40–50.
22. Ludwig W, Phillips M. Organic causes of erectile dysfunction in men under 40. Urol Int. 2014;92:1–6.
23. Capogrosso P, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man — worrisome picture from the everyday clinical practice. J Sex Med. 2013;10:1833–1841.
24. Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D. Prevalence of erectile dysfunction among young adults: results of a large-scale survey. J Sex Med. 2004;1:284–291.
25. Sanders SA, et al. General erectile functioning among young, heterosexual men who do and do not report condom-associated erection problems (CAEP) J Sex Med. 2015;12:1897–1904.
26. Papagiannopoulos D, Khare N, Nehra A. Evaluation of young men with organic erectile dysfunction. Asian J Androl. 2015;17:11–16.
27. Yao F, et al. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin Res Cardiol. 2013;102:645–651.
28. Salonia A, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function–Erectile Function domain. J Sex Med. 2012;9:2708–2715.
29. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191–236.
30. Saenz de Tejada I, Kim N, Lagan I, Krane RJ, Goldstein I. Regulation of adrenergic activity in penile corpus cavernosum. J Urol. 1989;142:1117–1121. A seminal paper on cell signalling in the corpora cavernosum.
31. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802–1813.
32. Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137:829–836.
33. Michel’s G, Hoppe WC; Rapid actions of Andogens, Front Neuro Endocrinol 29;182,2008
34. Lahn BT, Pearson NM, Jegalian KI. The human Y chromosome, in the light of evolution, Nat Rev Genet 2; 207, 2001.